- Conditions
- Glioblastoma
- Interventions
- Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma
- Interventions
- BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Fayetteville, Arkansas • Boston, Massachusetts • Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Nativis Voyager
- Device
- Lead sponsor
- Nativis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
- Interventions
- Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
- Drug
- Lead sponsor
- Leaf Vertical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
- Interventions
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Glioblastoma
- Interventions
- IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
- Combination Product · Procedure · Drug
- Lead sponsor
- Imvax
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Detroit, Michigan + 15 more
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Interventions
- DB107-RRV, DB107-FC, Radiation Therapy (RT), Temozolomide, Magnetic Resonance Imaging (MRI), Surgical resection
- Genetic · Drug · Radiation + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 2 more
- Conditions
- Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
- Interventions
- Niraparib, Temozolomide
- Drug
- Lead sponsor
- Ivy Brain Tumor Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
- Conditions
- Glioblastoma, GBM
- Interventions
- 5-ALA HCl + LIDU SDT, Placebo + Sham SDT
- Combination Product
- Lead sponsor
- Alpheus Medical, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Interventions
- AL58805, AL3818, Temozolomide (TMZ), CCNU
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 4 more
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype
- Interventions
- Cerebraca wafer, Temozolomide (for relapsed malignant glioma)
- Drug
- Lead sponsor
- Everfront Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Interventions
- P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy, temozolomide, Filgrastim, carmustine
- Biological · Drug · Radiation
- Lead sponsor
- Leland Metheny
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Newly Diagnosed High Grade Glioma
- Interventions
- Temozolomide, conformal brain radiation therapy, Nivolumab, Ipilimumab, Bevacizumab, 5-day Temozolomide, Lomustine, Nivolumab monotherapy
- Drug · Radiation
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Glioblastoma Multiforme
- Interventions
- Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
- Biological · Drug · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
- Device · Drug
- Lead sponsor
- CarThera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Glioblastoma (GBM)
- Interventions
- DOC1021, Tumor resection, Temodar (Temozolomide), SOC cranial radiation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Diakonos Oncology Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • Newport Beach, California + 14 more